Some patients may switch to copycats of another GLP-1 drug, semaglutide, the main ingredient in the type 2 diabetes drug Ozempic and the weight loss drug Wegovy. Semaglutide remains on the FDA’s ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...

Whenever a new year begins, most of us strive to make some resolutions such as going to the gym, drinking less (aka, Sober ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...